Tolerance Bio Licenses Long-Acting IL-7 Therapy

Philadelphia, Pennsylvania, August 19, 2026

Tolerance Bio Advances Thymus-Focused Drug Development

The licensing agreement gives Tolerance Bio access to a clinical-stage therapeutic with substantial human clinical experience. Efineptakin alfa has been evaluated in more than 800 subjects across 15 clinical studies, generating safety, tolerability, pharmacologic, and clinical data that the companies say support continued development. Tolerance Bio expects HIV immunological non-response, a condition characterized by inadequate immune recovery despite antiretroviral therapy, to be among the initial indications evaluated in Phase 2. The company is pursuing thymic biology as a therapeutic strategy because the thymus plays a central role in T-cell maturation and immune competence but progressively declines with age and can be affected by infections and chronic inflammatory conditions. This decline can contribute to reduced immune resilience, increased susceptibility to infections, impaired vaccine responses, and other immune-related challenges. Tolerance Bio aims to develop therapies capable of supporting thymic function and maintaining healthier immune responses in vulnerable populations.

Long-Acting IL-7 Therapy Supports Immune Resilience

Efineptakin alfa is a next-generation long-acting IL-7 fusion protein engineered to provide sustained IL-7 activity. The molecule contains two IL-7 moieties stabilized through N-terminal engineering and genetically fused to an hyFc long-acting platform, which is designed to extend its half-life. IL-7 is an important cytokine involved in thymic function and T-cell differentiation, proliferation, and survival. According to the company, clinical experience with IL-7 has demonstrated increases in thymic and T-cell activity in certain immunologically vulnerable populations, including people with cancer and people living with HIV who have inadequate immune recovery. These observations provide a scientific rationale for evaluating long-acting IL-7 as a potential approach to improving immune reconstitution. Tolerance Bio plans to investigate efineptakin alfa in indications aligned with its strategy of preserving thymic T-cell output and immune resilience, while future research could explore broader applications of thymus-directed therapies.

Strategic License Expands Tolerance Bio Pipeline

The addition of efineptakin alfa expands Tolerance Bio’s emerging pipeline across multiple therapeutic modalities targeting thymus biology. Alongside biologic therapies, the company is developing thymus-targeted mRNA and thymus cell therapies, with the goal of preserving, regenerating, and modulating thymic function through complementary approaches. Under the licensing agreement, NeoImmuneTech is eligible for potential development and sales milestone payments of up to $260 million, in addition to equity consideration and tiered royalties based on net sales. For NeoImmuneTech, the collaboration provides an opportunity to advance NT-I7 in new thymus-related indications through a partner specifically focused on thymic biology. For Tolerance Bio, the agreement provides a pathway to rapidly enter clinical development with a molecule that already has a substantial body of clinical experience. The planned Phase 2 program could generate additional evidence regarding the ability of efineptakin alfa to enhance thymic function and improve immune resilience in immunologically vulnerable populations. The transaction therefore represents a significant milestone in the development of thymus-focused therapeutics and highlights growing interest in strategies designed to address immune decline through targeted biological interventions.

Source: Tolerance Bio press relese